Abstract
Background: The global prevalence of AMD is projected to be 196 million by the year 2020. Despite substantial progress in the development of new therapies for wet AMD using inhibition of vascular endothelial growth factor (VEGF), the severe visual impairment associated with geographic atrophy in dry AMD remains untreatable. A number of therapeutic options for dry AMD are being developed and are in various stages of clinical trials.
Methods: Review of literature. Results: Enhancers of choroidal blood flow, neuroprotectants and anti-complement factors are the key targets in the research for the treatment of dry AMD. These molecules aim to promote the function of the retinal pigment epithelium and preserve the photoreceptors. Conclusion: New molecules are being developed for the treatment of dry AMD, and anti-complement therapy appears to be the most promising among them.Keywords: Age-related macular degeneration, geogrpahic atrophy, drusen, complement, neuroprotectant, visual cycle, choroidal blood flow.
Current Pharmaceutical Design
Title:Hot Topics in Dry AMD
Volume: 23 Issue: 4
Author(s): Raja Narayanan and Baruch D. Kuppermann
Affiliation:
Keywords: Age-related macular degeneration, geogrpahic atrophy, drusen, complement, neuroprotectant, visual cycle, choroidal blood flow.
Abstract: Background: The global prevalence of AMD is projected to be 196 million by the year 2020. Despite substantial progress in the development of new therapies for wet AMD using inhibition of vascular endothelial growth factor (VEGF), the severe visual impairment associated with geographic atrophy in dry AMD remains untreatable. A number of therapeutic options for dry AMD are being developed and are in various stages of clinical trials.
Methods: Review of literature. Results: Enhancers of choroidal blood flow, neuroprotectants and anti-complement factors are the key targets in the research for the treatment of dry AMD. These molecules aim to promote the function of the retinal pigment epithelium and preserve the photoreceptors. Conclusion: New molecules are being developed for the treatment of dry AMD, and anti-complement therapy appears to be the most promising among them.Export Options
About this article
Cite this article as:
Narayanan Raja and Kuppermann D. Baruch, Hot Topics in Dry AMD, Current Pharmaceutical Design 2017; 23 (4) . https://dx.doi.org/10.2174/1381612822666161221154424
DOI https://dx.doi.org/10.2174/1381612822666161221154424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ins and Outs of RNAi in Mammalian Cells
Current Pharmaceutical Biotechnology Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy HIV-Antigens Charged on Phosphorus Dendrimers as Tools for Tolerogenic Dendritic Cells-Based Immunotherapy
Current Medicinal Chemistry SUBJECT INDEX TO VOLUME 1
Current Genomics Role of Phosphorylation in the Nuclear Biology of HIV-1
Current Medicinal Chemistry Hydrogen Sulfide in Gastrointestinal and Liver Physiopathology
Inflammation & Allergy - Drug Targets (Discontinued) Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Recombination Functions of Replication Protein A
Current Organic Chemistry Dual COX-Inhibitors: The Answer is NO?
Current Topics in Medicinal Chemistry Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
Current Drug Targets Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
CNS & Neurological Disorders - Drug Targets Microarray Analysis Reveals CCL24/Eotaxin-2 as an Effector of the Pathogenetic Effects Induced by HIV-1 Nef
Current Drug Discovery Technologies COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease
Current Alzheimer Research Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Transient Expression of Recombinant sPDGFRα-Fc in CHO DG44 Cells using 50-mL Orbitally Shaking Disposable Bioreactors
Protein & Peptide Letters Relation Between Helicobacter Pylori Infection and Gastroduodenal Diseases
Current Cancer Therapy Reviews PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution
Current Drug Metabolism